Study

EORTC-1913-LYMG

A randomised phase III trial with a PET response adapted design comparing ABVD +/- ISRT with A2VD +/- ISRT in patients with previously untreated stage IA/IIA Hodgkin lymphoma.

Study documentation Back to result

Trial Status

Recruiting

Dates

Date of activation: 01-Mar-2024

Data management at EORTC

No

Design

Phase 3
Randomized open label

Targeted Sample size

Treatment

Drug
Bleomycin, Dacarbazine, Doxorubicin, Vinblastine, Brentuximab vedotin

Study Staff

  • Martin Hutchings (Study Coordinator), Rigshospitalet, Copenhagen
  • Amelie Baudhuin (Clinical Operations Assistant), EORTC Headquarters, Brussels
  • Emanuel Buhrer (Project Physician), EORTC Headquarters, Brussels
  • Benedicte Demeulder (Project Manager), EORTC Headquarters, Brussels
  • Catherine Fortpied (Statistician), EORTC Headquarters, Brussels
  • Leslie Herman (Regulatory Affairs Manager), EORTC Headquarters, Brussels
  • Juliette Ly (Project Manager), EORTC Headquarters, Brussels
  • Cedric Mallien (Clinical Operations Manager), EORTC Headquarters, Brussels
  • Nathalie Ropson (Regulatory Affairs Manager), EORTC Headquarters, Brussels
  • Ward Sents (Clinical Scientist), EORTC Headquarters, Brussels
  • Jelle Stans (Regulatory Affairs Manager), EORTC Headquarters, Brussels
  • Bette Stofs (Pharmacovigilance Manager), EORTC Headquarters, Brussels
  • Sanne Tonino (Study Co-Coordinator), Amsterdam UMC - Locatie AMC, Amsterdam
  • Sofie Verschueren (Clinical Operations Manager), EORTC Headquarters, Brussels

Type of cancer

  • Hodgkins Disease

Participating groups

  • EORTC Lymphoma Group
  • University College of London

Recruiting centers

  • AZ Delta - Campus Rumbeke (Roeselare, Belgium)
  • Amsterdam UMC - locatie VUMC (Amsterdam, Netherlands)
  • Hospital Del Mar (Barcelona, Spain)
  • ICO L’Hospitalet - Hospital Duran i Reynals (Institut Catala D'Oncologia) (L' Hospitalet De Llobregat, Spain)

Centers to be activated

  • Amsterdam UMC - Locatie AMC (Amsterdam, Netherlands)
  • CHU Site Sainte-Elisabeth-UCL Namur (Namur, Belgium)
  • Complejo Hospitalario de Navarra (Pamplona, Spain)
  • Haaglanden MC - locatie Antoniushove ( Leidschendam, Netherlands)
  • Instituto Portugues de Oncologia de Lisboa Francisco Gentil – EPE (Lisboa, Portugal)
  • Narodny Onkologicky Ustav - Bratislava (Bratislava, Slovakia)
  • Radboud University Medical Center Nijmegen (Nijmegen, Netherlands)
  • Region Midtjylland - Aarhus University Hospital-Skejby (Aarhus, Denmark)
  • Reinier De Graaf Gasthuis (Delft, Netherlands)
  • Rigshospitalet (Copenhagen, Denmark)
  • St. James'S Hospital (Dublin, Ireland)
  • St. Vincent'S University Hospital (Dublin 4, Ireland)
  • U.Z. Leuven - Campus Gasthuisberg (Leuven, Belgium)
  • Universitair Ziekenhuis Antwerpen (Edegem, Belgium)
  • University Hospital Galway (Galway, Ireland)
  • University Medical Center Groningen (Groningen, Netherlands)
  • ZNA CADIX (Antwerpen, Belgium)

Protocol summary

http://clinicaltrials.gov/study/NCT04685616

NCT number

NCT04685616

EudraCT

2020-005160-65